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Abstract 
Introduction: Stargardt macular dystrophy (STGD1) is a hereditary retinal degeneration 
that lacks effective treatment options. Gene therapy, stem cell therapy, and 
pharmacotherapy with visual cycle modulators (VCMs) and complement inhibitors are 
discussed as potential treatments. 
Areas Covered: Investigational therapies for STGD1 aim to reduce toxic bisretinoids and 
lipofuscin in the retina and retinal pigment epithelium (RPE). These agents include C20-
D3-vitamin A (ALK-001), isotretinoin, VM200, emixustat, and A1120. Avacincaptad 
pegol is a C5 complement inhibitor that may reduce inflammation-related RPE damage. 
Animal models of STGD1 show promising data for these treatments, though proof of 
efficacy in humans is lacking. Fenretinide and emixustat are VCMs for dry AMD and 
STGD1 that failed to halt geographic atrophy progression or improve vision in  trials for 
AMD. A1120 prevents retinol transport into RPE and may spare side effects typically 
seen with VCMs (nyctalopia and chromatopsia). Stem cell transplantation suggests 
potential biologic plausibility in a phase I/II trial. Gene therapy aims to augment the 
mutated ABCA4 gene, though results of a phase I/II trial are pending. 
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Hussain, R. M., Ciulla, T. A., Berrocal, A. M., Gregori, N. Z., Flynn, H. W., & Lam, B. L. (2018). Stargardt macular dystrophy and 
evolving therapies. Expert Opinion on Biological Therapy, 18(10), 1049–1059. https://doi.org/10.1080/14712598.2018.1513486
Expert Opinion: Stem cell transplantation, ABCA4 gene therapy, and VCMs offer 
biologically plausible treatment mechanisms for treatment of STGD1. Further trials are 
warranted to assess efficacy and safety in humans. 
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1. Introduction 
 Autosomal recessive Stargardt macular dystrophy (STGD1) is a retinal dystrophy 
resulting from mutations in the ATP-Binding Cassette, subfamily A, member 4 (ABCA4) 
gene. It is the most common form of inherited macular degeneration, affecting roughly in 
1 in 10,000 people. The age of onset of juvenile and early adult STGD1 is usually 8–25 
years with some cases occurring in older adults (late-adult onset STGD1) [1, 2]. These 
patients develop irreversible vision loss due to atrophy of the macular retinal pigment 
epithelium (RPE) and loss of photoreceptors, with patients presenting at a younger age 
having worse visual outcomes compared to those with later onset [1].  
 
1.1 Clinical Presentation 
The phenotypes of STGD1 are heterogeneous and distinct phenotypic groups of 
STGD1 are recognized. Early-onset childhood STGD1 typically affects children age 6 to 
12 years causing rapid severe decline in visual acuity over 12 to 24 months. Clinical 
findings in the posterior pole are sometimes subtle, showing rare peripheral flecks and 
mild macular changes, but dramatic macular atrophy can be apparent on OCT and 
autoflouresence [3]. Juvenile and young adult forms of STGD1 have varying degree of 
macular atrophy and distribution of flecks with a wide spectrum of progression. Late 
onset forms of STGD1 usually have perifoveal atrophy with preserved foveal function 
and structure that subsequently degenerate in later adulthood [4].  
  
 A hallmark of the disease is premature accumulation of lipofuscin (a brown-
yellow autofluorescent pigment associated with aging) in the RPE, causing a pattern of 
yellowish flecks that extend outward from the macula, recently though to represent 
degenerated photoreceptor cells [5-7] (Figure 1). The diffuse accumulation of this 
lipofuscin material results in the classic dark or “silent” choroid identified on fluorescein 
angiography due to masking of choroidal fluorescence (Figure 2) [8]. On funduscopic 
examination, patients may demonstrate an atrophic or a bull’s-eye appearance in the 
macular region, even more apparent on fundus autofluorescence (FAF) (Figure 3) [9, 10]. 
Lipofuscin is also found in cells of the liver, kidney, heart muscle, adrenals, and nerves, 
and is considered one of the most consistent morphologic features of aging, with a degree 
of accumulation inversely related to age [11, 12]. However, it is thought that the 
mechanisms involved in RPE lipofuscin formation are closely related to metabolic 
pathways that are specific to the retina and fundamentally different from mechanisms 
found in other tissues (described in Section 1.2) [13]. 
 The RPE is essential for the neurosensory retina homeostasis. It acts as a transport 
exchange system with blood capillaries and is critical for phagocytosis of photoreceptor 
outer segments. However, rising RPE lipofuscin levels contributes to a decline in 
photoreceptor and RPE function, resulting in the degeneration of the macula with 
subsequent loss of central vision [14, 15]. Figure 4 shows a spectral domain optical 
coherence tomography (SD-OCT) image of a patient with STGD1, demonstrating 
atrophic retina with RPE and photoreceptor irregularities. 
In the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies, 
valuable information about the natural history of this disorder is being collected.  Over 
200 STGD1 patients were enrolled in this natural history study across multiple clinical 
sites.  Change in best-corrected visual acuity (BCVA) over a 12-month period was 
minimal, and varied depending on baseline acuity, and consequently was not a sensitive 
1-year outcome measure [17]. However, microperimetry is being assessed as a potentially 
more accurate functional outcome measure for future clinical trials [18].  In ProgStar, 
anatomic endpoints to assess progression of atrophy through both FAF and OCT are 
being assessed [19, 20].  
 
1.2 Molecular Genetics 
 ABCA4 acts as a membrane transporter for the recycling of chromophores (11-cis-
retinal) during the visual cycle. Specifically, ABCA4 encodes for a photoreceptor outer 
segment rim protein, a “flippase” whose function is to transport the all-trans –
retinaldehyde-phosphatidylethanolamine (retinaldehyde-PE) Schiff base and excess 11-
cis-retinal from the luminal/extracellular leaflet to the cytoplasmic leaflet of rod and cone 
photoreceptor disc membranes, where they can then be transformed back to retinol [21, 
22]. Without its functional transporter, the retinaldehyde-PE conjugates may react to 
form vitamin A dimers (bisretinoids, some of which include A2E and ATR-dimer), which 
then accumulate in the RPE after phagocytosis of the photoreceptors outer segments. 
Vitamin A dimers are toxic to cultured RPE cells and are thought to play a significant 
role in lipofuscin formation and subsequent retinal degeneration [23, 24].  Experimental 
models of cultured RPE cells have suggested that A2E sensitizes RPE cells to light-
induced apoptosis [25] and has an inhibitory effect on phospholipid digestion in RPE 
phagolysosomes. This may result in accumulation of undigested waste products in the 
RPE that contributes to degeneration, though this has not been confirmed in human or 
STGD1 mouse models [26].  
 Lipofuscin also originates from the free 11-cis-retinal that is continuously 
supplied to the rod for rhodopsin regeneration and outer segment renewal. A2E and 
lipofuscin are produced in the dark as well as in the light, and ABCA4 plays a role in 
removing 11-cis retinal in excess of that needed to combine with opsin to regenerate 
rhodopsin [22]. Hence, loss in the function of ABCA4 can result not only in the 
accumulation of all-trans retinal generated by photobleaching of rhodopsin, but also 
excess 11-cis retinal from the visual cycle. These retinoids can then produce A2E and 
related compounds found in lipofuscin deposits. 
 More recently, the ABCA4 gene was found to be expressed not only in the 
photoreceptor outer segments, but also the RPE cells. Consequently, ABCA4 mutations 
may have a pathogenic role in both the photoreceptors and RPE cells, which could impact 
gene therapy, with regard to the need to potentially transduce both the photoreceptor and 
RPE layers (Farnoodian-Tedrick, et al, ARVO E-Abstract 198, 2018). 
 At the current time, there are no commercially available treatments for STGD1. 
Investigational therapies include visual cycle modulators (VCMs) that aim to reduce 
accumulation of Vitamin A dimers, complement inhibitors, gene therapy, and human 
embryonic stem-cell therapy for regeneration of the RPE. These treatments are 
summarized in Table 1. 
 
2. Pharmacotherapy to treat Stargardt Macular Dystrophy 
2.1 Introduction to Visual Cycle Modulators 
 The visual cycle is a series of enzymatic reactions that take place in the outer 
retina photoreceptors and RPE that converts all-trans retinal to 11-cis retinal for the 
regeneration of rhodopsin. As understanding of the visual cycle progresses, the ability to 
manipulate it to treat retinal disease has advanced. 
 The rods are single photon receptors that allow visual perception in low 
illumination, while the cones are less sensitive but can distinguish various wavelengths of 
light, to facilitate color vision.  Both rods and cones use 11-cis-retinal, which binds to 
opsins to then form visual pigments such as rhodopsin or cone opsins [27].  When light 
strikes rhodopsin (composed of the protein opsin bound to the chromophore 11-cis-
retinal, a vitamin A derivative) in the rod outer segments, 11-cis-retinal is converted to its 
all-trans-retinal isomer.  This, in turn, activates the opsin and initiates a signal 
transduction cascade, closing a cyclic GMP-gated cation channel, and hyperpolarizing the 
photoreceptor cell. The all-trans-retinal must be converted back to 11-cis-retinal, through 
a sequence of reactions catalyzed by enzymes, including retinol dehydrogenases (RDH), 
which catalyze reduction and oxidation reactions in the photoreceptor, as well as lecithin 
retinol acyltransferase (LRAT) and retinoid isomerohydrolase (a 65 kilodalton protein, 
encoded by the RPE65 gene), both of which are located in the RPE [28]. The visual cycle 
is diagrammed in Figure 5, which also shows the role of select therapeutics that influence 
the visual cycle.  
 Although necessary for vision, 11-cis-retinal in excess (like all-trans-retinal) can 
be toxic due to its highly reactive aldehyde group. It must be detoxified by either 
reduction to retinol or sequestration within retinal-binding proteins.  It has been 
demonstrated that ABCA4 can transport N-11-cis-retinylidene- PE, the Schiff-base 
conjugate of 11-cis-retinal and PE, from the lumen to the cytoplasmic leaflet of disc 
membranes. This transport role together with chemical isomerization to its all-trans 
isomer and reduction to all-trans-retinol by RDH can prevent accumulation of excess 11-
cis-retinal and its Schiff-base conjugate, and the formation of toxic bisretinoid 
compounds [29].  
 It has been demonstrated that the RPE visual cycle, which supplies chromophore 
to both rods and cones, is too slow to support cone function under bright conditions [30]. 
Additionally, pigment regeneration is rate-limited by the supply of recycled chromophore 
to the photoreceptors [31], suggesting that chromophore is supplied faster to cones than 
to rods, possibly with the help of a second, cone-specific visual cycle. This cone-specific 
visual cycle depends on Müller cells instead of the RPE to regenerate chromophores [32]. 
This second pathway could serve as a target for future therapies, though the authors are 
unaware of any that exist at this time. 
  The visual cycle plays a key role in several retinal disorders aside from STGD1.  
For example, dysfunction of enzymes in the visual cycle leads to several inherited retinal 
diseases (IRDs) such as retinitis pigmentosa (RP) and Leber’s congenital amaurosis 
(LCA), due to the inability to either produce an adequate supply of 11-cis-retinal or an 
inability to remove the accumulation of various retinoid products. The visual cycle has 
become the focus of therapeutic strategies as several compounds have the potential to 
address defects in this cycle to treat rare IRDs.  Several clinical trials have assessed these 
investigational VCMs with the goal of potentially slowing the progression of STGD1 and 
age-related macular degeneration (AMD), the leading cause of irreversible blindness in 
the industrialized world.  
 
2.2 Decrease Toxic Byproducts of ABCA4 Dysfunction: ALK-001 (C20-D3-vitamin 
A) 
 The rate determining step in vitamin A dimerization is the cleavage of a C20 
carbon-hydrogen bond of the retinaldehyde-PE Schiff base [33]. Replacing the C20 
hydrogen atoms of vitamin A with deuterium atoms (i.e. C20-D3 -vitamin A) makes this 
bond harder to cleave and impedes vitamin A dimerization. Several studies have sought 
to determine whether slowing the intrinsic reactivity of vitamin A to dimerize could slow 
lipofuscin formation in the RPE and delay changes associated with human STGD1. In an 
experimental mouse model of STGD1, ABCA4-/- mutant albino mice were raised on diets 
containing either C20-D3 –vitamin A (the treated group) or vitamin A at its natural 
isotopic abundance (the control group). The concentration of vitamin A dimers, 
lipofuscin and other biological markers indicative of ocular health in both groups were 
measured. Treated mice exhibited an 80% reduction in A2E, a 95% reduction in ATR 
dimer and a 70% decrease in fundus autofluorescence at three months of age. After six 
months, the treated group showed fewer lipofuscin granules as visualized qualitatively by 
electron microscopy, and at 12 months they showed improved eye function as measured 
by electroretinogram (ERG). These results suggest that pathological phenotypes that arise 
from defects in the ABCA4 gene may result from the dimerization of vitamin A and may 
be improved by hindering the ability of vitamin A to dimerize [34].  
 Similar results were found in another mouse model of STGD1, in which Vitamin 
A dimerization contributed to over 50% of lipofuscin accumulation and caused 
transcriptional dysregulation of several complement genes associated with inflammation 
[35]. Replacing Vitamin A with C20-D3-vitamin A impeded dimerization of Vitamin A 
(by approximately five-fold for A2E), and additionally normalized the aberrant 
transcription of complement genes without impairing retinal function. Phenotypic rescue 
by C20-D3-vitamin A was also observed noninvasively by quantitative autofluorescence 
in as little as 3 months after the initiation of treatment, whereas upon interruption of 
treatment, the age-related increase in autofluorescence resumed. These results further 
indicate that administration of C20-D3 -vitamin A may be a feasible therapeutic approach 
to slow the progression of associated retinal disease caused by Vitamin A dimerization. 
During these mice studies, no side effects were noted, and the animals were administered 
the drug for 12 months. 
 The promising results of the aforementioned pre-clinical studies have paved the 
way for the oral once-daily C20-D3-vitamin A molecule, ALK-001 (Alkeus 
Pharmaceuticals, Boston, MA), to begin human clinical trials in STGD1. A Phase 1 trial 
(NCT02230228) to assess the safety and pharmacokinetics in healthy volunteers has been 
completed [36]. The phase 2 TEASE study (NCT02402660) is ongoing [37].  
 
2.3 Decrease Toxic Byproducts of ABCA4 Dysfunction:  VM200 
 Vision Medicine’s VM200 molecule for STGD1 is currently in pre-clinical trials. 
This oral aldehyde trap sequesters the toxic compound, all-trans retinal, to potentially 
prevent retinal cell death [38].  Specifically, VM200 is a primary amine that reacts with 
the aldehyde group of all-trans retinal to form an inactive Schiff base, thus making it 
unable to form A2E. VM200 was shown to preserve retinal structure in ABCA4-/- Rdh8-/- 
mice, as measured by SD-OCT. According to unpublished data from Case Western 
Reserve University, VM200 has also demonstrated ability to preserve retinal function, as 
mice treated with it were noted to have increased concentration of 11-cis retinal (a 
biomarker of intact photoreceptors) compared to controls [39]. No significant toxicities 
were noted in 2-week and 13-week long studies. The molecule of VM200 is an 
enantiomer of pregabalin, which is used to treat neuropathic pain, though its affinity for 
the pregabalin target is 10-fold less than that of pregabalin. VM200 could also have 
therapeutic potential in other inborn errors of aldehyde metabolism including Sjogren-
Larsson Syndrome, Best Disease, and Succinic semialdehyde-dehydrogenase deficiency. 
Pre-clinical studies are continuing [39].  
 
2.4 Inhibition of 11-cis-retinol dehydrogenase: Isotretinoin 
 Isotretinoin (Accutane) is a drug indicated for the treatment of acne.  It has also 
been shown to inhibit lipofuscin formation in a mouse model [40] by inhibiting 11-cis-
retinol dehydrogenase in the visual cycle, thus slowing the synthesis of 11-cis-
retinaldehyde and regeneration of rhodopsin. This explains the side effect of decreased 
night vision in patients who use isotretinoin for acne [41] , though isotretinoin has not 
been shown to induce photoreceptor degeneration, and actually protects against light-
induced damage [42]. Light activation of rhodopsin results in its release of all-trans-
retinaldehyde, which constitutes the first reactant in toxic A2E biosynthesis. ABCA4-/-  
mice that were injected with isotretinoin had decreased production of A2E, along with 
less formation of lipofuscin granules in the retina compared to controls, as viewed by 
electron microscopy. Additionally, wildtype mice treated with isotretinoin for 2 months 
had a 40% reduction of A2E formation in the RPE compared to controls. On ERG, both 
wild-type and ABCA4-/- mice showed smaller delays in dark adaptation after isotretinoin 
administration with bright compared with dim probe flashes. These results suggest that 
isotretinoin reduced rhodopsin levels in both wild-type and ABCA4-/- retinas. The authors 
propose that isotretinoin may delay visual loss in STGD1 and other retinal diseases 
linked to lipofuscin accumulation. 
 
2.5 Inhibition of RPE65: Emixustat. 
 Emixustat (ACU-4429, developed by Acucela Inc) is a small non-retinoid 
derivative of retinylamine that inhibits retinoid isomerohydrolase (encoded by the RPE65 
gene), thus reducing the conversion of all-trans-retinyl ester to 11-cis-retinol and 
preventing accumulation of A2E. Phase 1 studies showed that the drug was well-tolerated 
up to 75 mg with expected dose dependent suppression of scotopic ERG in healthy 
subjects [43].  It was initially developed as an investigational agent to potentially slow 
the progression of geographic atrophy (GA) in age-related macular degeneration (AMD), 
but it is also being assessed as a potential treatment for STGD1. 
 
 In May 2016, Acucela announced the results of its Phase 2b/3 “S.E.A.T.T.L.E.” 
clinical trial, which was designed to determine if emixustat could reduce the growth rate 
of GA compared to placebo. The study failed to meet its primary endpoint, as there was 
no statistically significant difference in lesion growth rate for any treatment group 
compared to placebo. There was no significant difference in the mean change of BCVA 
from baseline to month 24 between treatment groups. There was a small numerical 
treatment difference observed in certain patients with specific genetic profiles in favor of 
emixustat. The profile of adverse events was similar to that of earlier trials [44]. Acucela 
is currently assessing emixustat as a potential treatment for STGD1, and approximately 
30 patients were enrolled in a phase 2a study in the United States [45], and phase 2b/3 
study is planned. 
 
2.6 Retinol-binding protein antagonists: Fenretinide  
 Fenretinide (Sirion Therapeutics) is an oral synthetic retinoid derivative that 
competes with retinol to bind with retinol-binding protein 4 (RBP4), thus preventing 
transport of retinol into the RPE.  Serum retinol is maintained in circulation as a tertiary 
complex with RBP4 and transthyretin (TTR). Reduction in delivery of retinol-RBP-TTR 
to the RPE is thought to decrease accumulation of A2E, and may potentially slow vision 
loss in patients with STGD1 and AMD. Once fenretinide binds to RBP, the RBP-
fenretinide complex is rapidly eliminated in the urine [46].  Fenretinide has been shown 
to reduce formation of A2E in a mouse model of STGD1 [47]. Possible downsides to 
fenretinide therapy include its tendency to induce apoptosis in many cell types (including 
RPE) [48], along with teratogenic effects that would limits its use in women of child-
bearing age (more pertinent in treating STGD1 than AMD) [49]. 
 A recent phase 2 study assessed fenretidine (100 and 300 mg orally administered 
daily versus placebo) for slowing lesion growth in 246 patients with GA [50].  There was 
a dose-dependent reduction of serum RBP in fenretinide-treated patients.  There was also 
a trend for reduced annual lesion growth rates in patients in the 300 mg fenretinide group 
who achieved serum retinol levels of ≤1µM (1.70 mm2/year vs. 2.03 mm2/year, mean 
reduction of 0.33 mm2 compared to placebo, p = 0.1848). Only 51% of patients receiving 
300 mg and completing the 2-year study achieved this level of serum retinol reduction, 
resulting in a non-significant change in lesion growth rate versus the placebo group. RBP 
reductions < 2 mg/dL correlated with further reductions in lesion growth rates (r2= 
0.478). There was a 45% reduction in CNV formation among fenretinide groups, though 
all groups in the study lost a mean of 10-11 letters of vision at 2 year follow up, 
consistent with the natural history of GA and suggesting no visual benefit to the modest 
reduction in GA growth [50]. Furthermore, in the 300 mg fenretinide group, 20.2% of 
patients withdraw from the study due to adverse effects, though only complaints related 
to the skin or eye were thought to be drug related. The most common ocular adverse 
events that were reported (but did not necessarily lead to study withdrawal) included 
decreased visual acuity (71 %), night blindness (37.3 %), and visual disturbance (26.5 
%). 
 
2.7 Retinol-binding protein antagonists: A1120  
 A1120 (ICR-14967) is another drug that lowers serum retinol levels as a 
mechanism of potential treatment of STGD1. It was originally developed as a potential 
treatment for diabetes. Like fenretinide, A1120 is a RBP4 antagonist, though A1120 
differs in that it is not a retinoid and not an agonist to Retinoic Acid Receptor-alpha. This 
property may spare patients from the side effect profile associated with retinoids, which 
includes nyctalopia and delayed dark adaptation. ABCA4 -/- mice that were administered 
A1120 30 mg/kg daily for 6 weeks were found to have a 75% reduction of serum RBP4 
along with 50% reduction of lipofuscin bisretinoids compared to the control group. On 
ERG testing, no statistically significant difference in kinetics of the b-wave recovery after 
photobleaching was found between the groups of A1120- and vehicle-treated wild-type 
animals, suggesting that A1120's capacity for reduction of lipofuscin bisretinoids in the 
retina may not be associated with the appreciable suppression of the visual cycle. This 
finding supports the notion that A1120 is unlikely to cause side effects of nyctalopia or 
delayed dark-adaptation, which is seen in the other visual cycle modulators [51]. Based 
on this preclinical data, clinical trials are under development by a collaborative effort 
between iCura Vision, Columbia University, and the National Institutes of Health [51].  
 
2.8 Complement C5 inhibition: avacincaptad pegol (Zimura ®) 
 A2E and other bisretinoids are thought to have a pro-inflammatory effect by 
activation of the complement system in RPE cells [52-54]. Increased complement 
activation and inflammatory markers have been observed in ABCA4-/- mice, which has 
been associated with RPE dysfunction and photoreceptor degeneration [55]. C5 
complement plays a role in the terminal portion of the complement pathway, where the 
lectin, classical, and alternative complement pathways merge to form an inflammasome 
(a multi-protein complex responsible for activation of inflammatory responses) and 
membrane attack complex (MAC, involving complement C5b-9), both of which result in 
cell death [56]. 
 The antioxidant resveratrol and anti-C5 antibody have been shown to protect 
against RPE cell death in a cell culture model in which the RPE cells were exposed to 
bisretinoid-induced alternate complement pathway activation [54]. In a model of ABCA4-
/- mice, viral vector gene therapy was used to increase expression of complement receptor 
1-like protein (CRRY), a complement negative regulatory protein, in the RPE. This 
resulted in reduced complement levels of C3/C3b in the RPE, along with a 2-fold 
reduction in bisretinoid accumulation compared to sham-injected ABCA4-/- mice. On 
histologic evaluation, there were 30% fewer lipofuscin granules and significantly more 
photoreceptor nuclei in the outer nuclear layer compared to sham-injected ABCA4-/- mice 
after one year [57]. This study suggested that complement inhibition could be a feasible 
treatment option for preventing RPE and photoreceptor degeneration in STGD1. 
 Avacincaptad pegol (Zimura®, Ophthotech Corporation) is a C5 complement 
inhibitor which may prevent formation of the MAC, and consequently reduce cell death 
caused by destruction of the cell membrane. It is delivered by intravitreal injection and is 
being explored as a potential treatment option for a number of eye diseases including 
STGD1, dry AMD (GA), wet AMD, idiopathic polypoidal choroidal vasculopathy, and 
posterior uveitis [58]. A phase 2b study (NCT03364153) was initiated at the beginning of 
2018, which plans to follow approximately 120 STGD1 patients for 18 months. The 
primary endpoint of the study will assess the mean rate of change of the area of ellipsoid 
zone defects as measured by SD-OCT (Csaky KG, et al, ARVO E-Abstract 1569, 2018). 
For Dry AMD (GA) patients, a phase 1/2a clinical trial has already been completed, 
which showed that intravitreal injections of avacincaptad pegol were well-tolerated and 
there were preliminary signs of a relative dose-dependent decrease in growth of GA after 
monthly injection for 36 weeks [58, 59].  
 
3. ABCA4 Gene Therapy for Stargardt Macular Dystrophy 
 The goal of gene therapy for STGD1 is to introduce a functional ABCA4 gene to 
the retina, which will allow for expression of the membrane transporter and reduce 
buildup of toxic vitamin A dimers in the RPE. 
3.1 Introduction to viral vectors for gene therapy 
 
 A variety of viral and non-viral gene delivery methods have been developed over 
the past two decades. Choosing one delivery method over another is influenced by the 
tissue to be targeted, the cloning capacity of the vector (which determines the size of the 
expression cassette that can be accommodated in the genome of the virus), longevity of 
expression, and safety concerns (inflammatory responses, and possibility of 
genotoxicity/insertional oncogenesis). Adeno-associated virus (AAV) and lentivirus 
vectors have been used in the treatment of inherited retinal diseases, with AAV being the 
most common viral vector utilized [60].  
 
3.2 Methods of introducing viral vectors to the eye  
 
 Due to the ability to monitor functional changes in retinal disease, the eye 
provides an excellent model for investigating gene therapy. Additionally, the relative 
ocular immune-privilege limits an immune response to the implanted genetic material. 
Additional advantages include ease of accessibility for delivery of the genetic material 
directly to the target cells of interest, and the non-invasive ability to monitor for disease 
progression and response to therapy [61].    
 Vector delivery to the target retinal tissue involves two potential methods. The 
most commonly investigated method involves pars plana vitrectomy (PPV) followed by 
retinotomy and injection of the viral vector with genetic material into the subretinal 
space. This more invasive method creates a temporary retinal detachment, but allows for 
direct delivery to the cells of interest. The virus then “infects” the RPE cells or 
photoreceptors, causing the host cells own translational machinery to express the protein. 
Alternatively, injection of the vector into the vitreous cavity has been attempted, and 
although this method may be less invasive and potentially has fewer procedure-related 
complications, the penetration of viral vector to the target tissue is perceived to be 
inferior to that of subretinal injections [62]. Additionally, animal models have 
demonstrated an induced humoral immune response to intravitreally delivered vectors 
that was not observed with subretinally delivered vectors [63].  
 
3.3 EIAV-ABCA4 for Stargardt Macular Dystrophy 
 The ABCA4 gene (6.8 kb) far exceeds the 4.5-5.0 kb capacity of the AAV vector, 
leading to utilization of an equine infectious anemia lentivirus (EIAV) for gene transfer 
[64]. Subretinal injection of EIAV-ABCA4 was found to be effective in a knock out 
ABCA4 -/- mouse model, in which treated eyes had a significant reduction of A2E 
concentrations compared to untreated and mock-treated (EIAV-null vector) control eyes. 
Treated eyes of ABCA4 -/- mice accumulated 8-12 pmol per eye (s.d.=2.7) of A2E 1 year 
after treatment, amounts similar to wild-type controls, whereas mock-treated or untreated 
eyes had 3-5 times more A2E (27-39 pmol per eye, s.d.=1.5; P=0.001-0.005) [44]. 
  Further animal studies tested the safety and distribution of EIAV-ABCA4 in 
rabbits and macaques. In both species, there was a slightly higher amount of intraocular 
inflammation in eyes receiving the subretinal injection, though it was localized, transient, 
and did not cause toxicity. Intraocular pressure and ERG were unaffected, while 
histopathological evaluation did not reveal any detrimental effects of the subretinal 
injection. The vector remained in the ocular compartment, though a serum antibody 
response was observed in rabbits but not macaques, and did not result in any long-term 
systemic toxicity [65]. 
 Currently, Oxford Biomedica in coordination with Sanofi, is sponsoring an 
escalating dose Phase I/II clinical trial of SAR422459, formerly known as StarGen™ 
(NCT 01367444), investigating safety and preliminary signs of efficacy in STGD1 over a 
48 week follow up period [66] [60]. The trial, which plans to enroll an estimated 46 
patients, began in June 2011 and has an expected completion date in November 2019.  
Another study (NCT01736592) is assessing the long-term safety and tolerability of 
patients in the original SAR422459 trial, in which these patients are followed without 
further intervention for 15 years.  
 Another approach to address the large size of the ABCA4 gene, employs a dual 
AAV strategy instead of Lentivirus vector, which splits the gene into two AAV vectors. 
Inside the host cell, the two transgene fragments combine to generate the ABCA4 gene. 
One group recently presented preclinical work in a ABCA4 knock out mouse model 
showing that dual AAV vectors can be used to deliver ABCA4 gene, express protein, and 
have an effect on lipofuscin/A2E accumulation in this model (Dyka FM, et al. ARVO E-
Abstract 4533, 2018; Garanto A, et al. ARVO E-Abstract 4532, 2018).  
 An alternative to viral vector gene therapy is nanoparticle technology, which can 
accommodate large genes such as ABCA4 for injection into the subretinal space, have 
historically not shown long term gene expression in animal models. However, in a recent 
STGD1 mouse model, eyes that were injected with subretinal ABCA4 nanoparticles were 
found to have ABCA4 transgene expression that peaked at 2 months and lasted for up to 8 
months. The eyes showed reduced lipofuscin granules on histopathologic evaluation, and 
improvement of dark-adaptation recovery on ERG [67]. Based on these results, further 
study with nanoparticle gene therapy is warranted. 
 Another strategy involves oligonucleotides to address common splice defects in 
the ABCA4 gene.  At least two groups have presented preclinical work supporting this 
route for these specific mutations (Dulla K, et al. ARVO E-Abstract 5315, 2018).   
Antisense oligonucleotide-based treatment restores ABCA4 splicing defects caused by 
deep-intronic mutations associated with STGD1. Given the effect is not long lasting, 
repeat treatments via intravitreal injections have been proposed. 
 
4. Stem Cell Therapy for Stargardt Macular Dystrophy 
4.1 Introduction to stem cell therapy for retinal disease 
 Given that RPE cell dysfunction is thought to play a major role in the 
pathogenesis of STGD1, stem cell therapy has been explored as an option to rejuvenate 
or replace these damaged RPE cells. Stem cells can be derived from human embryonic 
stem cells (hESCs), induced pluripotent stem cells (iPSCs), and adult stem cells. Human 
ESCs have a great ability to divide and differentiate into a variety of cell types [68]. 
Induced pluripotent stem cells (iPSCs) are intriguing in that they can be derived from a 
previously differentiated cell source and have the potential for reduced ethical 
controversy over hESC- based therapies, and may negate immunological issues 
associated with hESC-based therapies. Like with gene therapy, the eye is an ideal 
candidate for stem cell research because the clear ocular media allows for direct 
visualization of transplanted cells and the eye is a relatively immune privileged site; 
furthermore, the size of the eye requires smaller quantities of therapeutic tissue in 
comparison to other organs [69]. Preclinical studies of hESC-derived RPE cells 
transplanted into the subretinal space of mouse models of retinal degeneration have been 
well tolerated and the cells sustained visual function and photoreceptor integrity in a 
dose-dependent fashion [70, 71]. 
 
4.2 hESC-derived RPE cell via subretinal transplantation for STGD1 
  Given the success of preclinical studies, phase I/II clinical trials were developed 
to test safety and preliminary signs of efficacy of subretinal transplantation of hESC-
derived RPE cells in patients with STGD1 and AMD (NCT01345006/NCT01469832). 
Nine subjects with atrophic AMD and nine with STGD1 were included and all had 
baseline visual acuity measuring from 20/200 to hand motion [72]. Patients underwent 
pars plana vitrectomy, followed by injection of 150 μl of terminally differentiated RPE 
cellular suspension into the subretinal space at preselected sites of transition between 
diseased and healthy retina. Patients received either 50,000 cells, 100,000 cells, or 
150,000 cells and were immunosuppressed with tacrolimus and mycophenolate mofetil 
from 1 week before surgery until 12 weeks following surgery, and thereafter as 
determined on individual basis [72]. 
 Following surgery, no signs of acute rejection were noted, such as prominent 
lymphocyte infiltration, acute or chronic moderate grade noninfectious uveitis, 
hyperacute rejection, cystoid macular edema, persistent retinal detachment, encapsulation 
of the transplanted cells, or whitening of the transplanted area. No eyes developed 
abnormal growth suggestive of a teratoma, a tumor comprised of two or more germ 
layers, which was seen in animals transplanted with suspension of RPE cells spiked with 
these hESC. No eyes developed proliferative vitreoretinopathy or a retinal detachment, 
although four patients developed a cataract and one developed endophthalmitis not 
associated with a subretinal abscess. These results support safety and tolerability of 
subretinal stem cell-derived RPE therapy [72].   
 Although visual outcomes without randomization and control group in phase 1/ 2 
trials are inconclusive, no alarming functional adverse events were noted. No significant 
changes were seen in visual field, static perimetry, ERG, or reading speed. Treated eyes 
that did not develop cataracts during at least 6 months of follow-up (n=5) improved by a 
median of ten letters at 1 month, 15 letters at 6 months, and 12 letters at 12 months 
whereas the fellow untreated eyes improved by a median of four letters at 1 month, four 
letters at 6 months, and two letters at 12 months. The National Eye Institute Visual 
Function Questionnaire revealed an improvement in the mental health and vision 
subscales for general vision, peripheral vision, near activities, and distance activities by a 
median of 8–20 points 3–12 months after transplantation of hESC-RPE [72]. A long-term 
follow-up study (NCT02445612) is following the same cohort of patients up to five years 
after stem cell implantation. Three-year results supported continued safety of the hESC-
RPE transplantation. The STGD1 patients gained a mean of 4.1 ETDRS letters in the 
treated eye and 3.3 letters in the untreated eye at 3 year follow up (5.8 and 4.0 letters, 
respectively, when excluding visually significant cataract) (Schwartz SD, et al. ARVO E-
Abstract 5004, 2018). Further studies by the same company will continue to explore 
safety and potential efficacy of hESC-derived RPE cells utilizing an updated cell line 
compliant with the current guidelines.  
 5. Conclusion  
 While there are currently no commercially available treatments for STGD1, there 
are several categories of therapeutics under investigation to potentially fulfill this unmet 
need. These include investigational VCMs, complement inhibitors, subretinal ABCA4 
gene replacement therapy (with viral vectors or nanoparticles), and subretinal 
transplantation of stem cell-derived RPE cells. 
 Pharmacological modulation of the visual cycle serves as a novel approach to the 
potential treatment of degenerative retinal diseases. Four classes of therapeutics, with 
mechanisms of action involving inhibition of vitamin A dimer accumulation in the retina, 
are emerging as potential treatments for STGD1. These include direct inhibitors of key 
visual cycle enzymes (isotretinoin and emixustat), RBP4 antagonists (fenretinide and 
A1120), primary amine-containing aldehyde traps (VM200), and deuterated analogs of 
vitamin A (ALK-001). Avacincaptad pegol is an investigational C5 complement inhibitor 
that aims to reduce inflammation-induced RPE cell death.  
 Gene therapy with subretinal injection of EIAV-ABCA4 (SAR422459) has been 
well-tolerated and successful in reducing A2E accumulation in animal models, thus 
paving the way for a phase I/II clinical trial that is expected to complete at the end of 
2019. A Phase I/II trial of subretinal transplantion of hESC-derived RPE cells has 
demonstrated safety and tolerability in a small cohort of STGD1 patients. 
 
6. Expert Opinion  
 
 As the pathophysiology of STGD1 is complex and not fully comprehended, a 
multi-targeted approach may be necessary to maximally halt the disease processes. 
Lipofuscin/bisretinoid accumulation, activation of the complement system, and chronic 
inflammation are all intertwined processes that could contribute to STGD1 progression to 
varying degrees. The emixustat and fenretinide trials both failed to show a statistically 
significant improvement in GA progression or BCVA in AMD patients, and also caused a 
notable amount of ocular and non-ocular side effects.  Still, their manufacturers hope for 
better results with these two drugs to prevent vision loss in STGD1 patients. 
 Since success in mouse models has not translated to meaningful success in human 
subjects, it is unclear if A2E reduction will enhance visual function in humans. There are 
many issues that can plague a clinical trial - for instance in a mouse model the phenotype 
is fairly constant. This is often not the case in human disease. The selection of patients in 
terms of disease stage is a difficult matter especially in clinical trials evaluating safety. 
Additionally, it is doubtful that patients in the real world would show compliance with a 
drug that causes nyctalopia and impaired dark adaptation. These are some of the issues 
that must be resolved before investigational VCMs become a feasible treatment option 
for STGD1.  
 Isotretinoin, which has been used as an acne treatment for many years with an 
acceptable safety proposal (aside from teratogenicity), has shown some promise in 
reducing lipofuscin formation in mouse models of STGD1, but there is a paucity of data 
to confirm its beneficial effect on humans with STGD1 at this point in time. C20-D3-
vitamin A (ALK-001) has shown similarly impressive results in reducing accumulation 
of Vitamin A dimers in the retina, along with improved ERG function in Stargardt mouse 
models, though the results of the completed phase 1 trial have not been released, to the 
best of the authors’ knowledge. 
 For management of STGD1, A1120, a RBP4 antagonist that lowers serum retinal 
levels, may one day serve as an intriguing option, as its developer suggests that it may not 
be associated with mechanism-based ocular side effects typical for direct visual cycle 
inhibitors, such as nyctalopia and delayed dark-adaptation [36]. However, given that it 
has only been tested in mouse models of STGD1, it is too soon to speculate about its 
potential efficacy in humans. Aldehyde trapping (VM200) could also theoretically 
represent an appealing approach to inhibiting retinal bisretinoid formation, as it may also 
lack the mechanism-based ocular side effects typical for direct visual cycle inhibitors. 
However, these compounds may need to be administered at very high systemic doses to 
act as aldehyde traps in the retina, which raises safety concerns. Local retinal delivery 
may be considered as an alternative to systemic administration of aldehyde traps to 
overcome potential systemic toxicities [36]. 
 Complement inhibition has been investigated as a treatment to potentially prevent 
progression of GA in dry AMD, but results have not been encouraging thus far, which 
casts uncertainty about potential efficacy for STGD1. Despite promising phase 2 results, 
intravitreal injections of the alternative pathway complement factor D inhibitor, 
lampalizumab (Roche/Genentech) failed to reduce GA area change from baseline in the 
twin phase 3 CHROMA and SPECTRI studies [37]. Intravenous infusion of the C5 
complement inhibitor, eculizumab (Alexion pharmaceuticals) also failed to significantly 
decrease the growth rate of GA in the phase 2 COMPLETE study [39]. It is unclear if 
avacincaptad pegol, another C5 complement inhibitor, will be more successful in 
AMD/STGD1, but perhaps intravitreal injection delivery may allow for better retinal 
drug levels than intravenous infusion.  
  Viral vector gene therapy has been approved for RPE65 mutation associated  
retinal dystrophy [60, 73], which has spurred interest in gene therapy for STGD1, 
although the ABCA4 gene is too large for AAV vectors and will require an alternative 
approach. Similar excitement surrounds the potential of stem cell therapy to treat STGD1. 
Although the Phase I/II hESC-RPE clinical trials provided encouraging safety results, the 
study is limited by the small sample size, relatively brief follow-up time, and lack of a 
control group. Further research is warranted to demonstrate safety and potential efficacy 
while improving methodologies of implantation.  
 
Article Highlights Box  
• Stargardt macular dystrophy (STGD1) is a hereditary retinal degeneration that 
may cause central vison loss and currently lacks therapies. 
• Investigational oral therapies for STGD1 aim to decrease accumulation of 
Vitamin A dimers and lipofuscin in the retina and RPE, and include ALK-001, 
isotretinoin, VM200, emixustat, and A1120. There is suggestion of efficacy in 
mouse models of STGD1, though evidence of efficacy in humans is currently 
lacking.  
• Visual cycle suppression is associated with nyctalopia, delayed dark-adaptation, 
and dyschromatopsia. 
• Intravitreal avacincaptad pegol is a C5 complement inhibitor under investigation 
for STGD1. 
• Embryonic stem cell derived RPE cell transplantation for STGD1 has shown early 
safety and tolerability in a small phase I/II clinical trial,  Further research will 
assess potential efficacy with respect to visual function and anatomic 
improvements.ABCA4 gene therapy with viral vectors and nanoparticles holds 
promise as a potential treatment for STGD1, though no results of a phase I/II trial 
are available at this time. 
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Figure 1. Fundus photo of a patient with STGD1 demonstrates atrophic retina with a 
“beaten bronze” appearance and surrounding yellow pisciform flecks extending outward 
from the fovea. 
 
Figure 2. Fluorescein angiography demonstrates classic dark or “silent” choroid due to 
masking of choroidal fluorescence. 
 
Figure 3. Fundus autofluorescence (FAF) accentuates the classic bull’s eye maculopathy. 
Abnormally increased FAF represents excessive lipofuscin accumulation in the RPE. 
Inversely, decreased areas of FAF relate to low level RPE metabolic activity, which 
normally underlies local atrophy with secondary photoreceptor loss.  
 
Figure 4. Spectral domain - optical coherence tomography demonstrates central retinal 
atrophy with outer retinal loss. 
 
Figure 5. The visual cycle pathway begins when light (orange starburst shape) interacts 
with rhodopsin (green diamond shape), setting off a series of steps catalyzed by enzymes 
(red cloud shapes). The chemical byproducts and investigational drugs are represented in 
blue box and purple oval shapes, respectively. The cross-through symbol denotes an 
inhibitory effect of a drug on the enzymes, while a plus sign indicates the effect of 
increasing rhodopsin levels.   RDH = retinol dehydrogenase, ABCA4 = ATP-Binding 
Cassette Subfamily A Member 4, LRAT = lecithin retinol acyltransferase, RPE = retinal 
pigment epithelium. 
